[6-[(3S,5R,7R,10S,13R,14S)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [6-[(3S,5R,7R,10S,13R,14S)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
• 化学式: C₃₄H₆₅N₃O₅S
• 分子量: 628.0
• InChiKey: UIRKNQLZZXALBI-ZRRPWJIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  142
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] OPHTHALMIC FORMULATIONS OF SQUALAMINE<br/>[FR] FORMULATIONS OPHTALMIQUES DE SQUALAMINE
  申请人：OHR PHARMACEUTICAL INC

  公开号：WO2017083799A1

  公开（公告）日：2017-05-18

  Ophthalmic compositions containing squalamine dilactate were unexpectedly observed to effectively treat ophthalmic conditions. The ophthalmic compositions may also be used in combination with other ophthalmic therapies.